  |
 |
 |
VOLUME
CONTROL VENTILATION VERSUS HFOV ON LUNG INFLAMMATION IN PRETERM
INFANTS |
|
 |
 |
 |
Dani
C, Bertini G, Pezzati M, et al. Effects of pressure
support ventilation plus volume guarantee vs. high-frequency
oscillatory ventilation on lung inflammation in preterm
infants. Pediatr Pulmonol. 2006; 41:
242-249.
(For non-journal subscribers, an additional fee
may apply for full text articles.) |
|
Lista
G, Castoldi F, Bianchi S, et al. Volume guarantee
versus high frequency ventilation: lung inflammation
in preterm infants. Arch Dis Child Fetal
Neonatal Ed. 2007; published on-line 3 Apr 2007.
(For non-journal subscribers, an additional fee
may apply for full text articles.) |
|
To
evaluate the abilities of High Frequency Oscillatory Ventilation
(HFOV) and VG to reduce lung inflammation, Dani et al performed
a prospective randomized study of 25 infants, <30 weeks
gestation, ventilated with HFOV or Pressure Support with Volume
Guarantee Ventilation (PSV-VG). The PSV-VG initial targeted
tidal volume was 5 ml/kg. Ventilator settings manipulation
in each group was based on specific blood gas criteria. Infants
were extubated within 2 hours of achieving standardized criteria,
with post-extubation support at the physician’s discretion.
Cytokine assays were measured at 4 specific intervals for
inflammation evaluation.
The study found no differences in secondary outcomes for mechanical
ventilation duration, need for oxygen therapy, nasal continuous
positive airway pressure (NCPAP) or second dose of surfactant,
length of ICU or hospital stay, or the development of patent
ductus arteriosus (PDA), pneumothorax, BPD, intra-ventricular
hemorrhage (IVH), PVL, retinopathy of prematurity (ROP), and
necrotizing enterocolitis (NEC). The mean values of IL-1b
(p= 0.042), IL-8 (p= 0.021), and IL-10 (p< 0.0001) at extubation
were significantly lower in HFOV infants. While IL-1b was
significantly less with HFOV, there was no change in PSV-VG
levels across the study duration. Interleukin (IL)-8 significantly
increased (p= 0.026) prior to extubation in pressure sensitive
ventilation (PSV)-VG ventilated infants, while remaining unchanged
in HFOV infants. IL-10 levels significantly increased in the
PSV-VG group at both 1 to 2 days of ventilation (p=0.028)
and prior to extubation (p=0.021), while significantly decreasing
in the HFOV group prior to extubation (p=0.026).
Lista’s group conducted a prospective, randomized study of
45 premature infants (gestation 25-32 weeks) to evaluate lung
inflammation between Assist/Control Volume Guarantee (AC-VG)
ventilation and HFOV during the acute phase of RDS. The AC-VG
initial targeted tidal volume was 5 ml/kg. Surfactant was
initially administered to all infants and re-dosed based on
standard criteria. Ventilator manipulations were based on
arterial blood gas values, and infants were extubated within
2-3 hours of achieving standardized criteria. Cytokine assays
were obtained prior to randomization and again at 3 days and
7 days post randomization.
Ventilation randomization was maintained until the 96th hour,
when HFOV neonates met unit criteria for switching to AC ventilation.
By day 7, no infants randomized to HFOV were still receiving
HFOV. Approximately two thirds of each group were receiving
AC-VG at the final aspirate sample, while one third of each
group were extubated and spontaneously breathing. The authors
report no differences in mechanical ventilation duration,
need for second dose of surfactant or postnatal steroids,
mortality, development of pulmonary hemorrhage, pneumothorax,
BPD, IVH, PVL, ROP, and NEC.
HFOV infants had significantly longer oxygen dependency (p<0.05).
Cytokines levels in AC-VG group were stable during the study.
IL-6 levels were significantly higher on day 3 (p<0.05)
and day 7 (p=0.03) in HFOV infants. HFOV also demonstrated
a trend for higher levels of IL-6, IL-8 and TNF-αlevels
on day 7 (p=0.09). Infants that developed BPD had high IL-8
(>20ng/ml) and TNF-α (>0.35ng/ml) levels on day
7.
Dani et al concluded that early HFOV treatment is associated
with reduced lung inflammation compared with PSV-VG in preterm
infants with RDS, while Lista et al concluded VG ventilation
is an effective lung-protective strategy to be used in acute
RDS, inducing a lower expression of early inflammation markers
when compared to HFOV. Each study had some limitations that
may explain the differences in conclusion (and highlight the
need for additional studies). Dani’s group used a spontaneous
breathing mode pressure-sensitive ventilation (PSV) as a comparator
to HFOV, a low positive and expiratory pressure (PEEP) (3-4
cm H20)
strategy, and possibly introduced study bias by allowing physicians
to change tidal volumes in (PSV)+VG. Limitations to Lista
et al include a relatively small number of patients, use of
a different high-frequency ventilator (Dräger Babylog
versus SensorMedics 3100), and the allowance of HFOV crossover
to AC+VG ventilation prior to study conclusion. |
|
 |
|
 |
|